Avadel Pharmaceuticals Plc's (NASDAQ:AVDL) Path To Profitability
Avadel Pharmaceuticals Plc's (NASDAQ:AVDL) Path To Profitability
Avadel Pharmaceuticals plc (NASDAQ:AVDL) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. The US$1.6b market-cap company's loss lessened since it announced a US$160m loss in the full financial year, compared to the latest trailing-twelve-month loss of US$157m, as it approaches breakeven. Many investors are wondering about the rate at which Avadel Pharmaceuticals will turn a profit, with the big question being "when will the company breakeven?" Below we will provide a high-level summary of the industry analysts' expectations for the company.
Avadel Pharmaceuticals(納斯達克:AVDL)可能即將實現業務上的重大成就,因此我們想介紹一下該公司。Avadel Pharmaceuticals是一家在美國經營的生物製藥公司。該市值爲16億美元的公司自宣佈全財年虧損1.6億美元以來,其虧損有所縮減,最新的過去12個月虧損爲1.57億美元,在接近盈虧平衡。許多投資者都在猜測Avadel Pharmaceuticals何時開始盈利,最大的問題是“該公司何時開始盈虧平衡?”以下是該公司行業分析師對該公司預期的高層次概述。
Avadel Pharmaceuticals is bordering on breakeven, according to the 9 American Pharmaceuticals analysts. They anticipate the company to incur a final loss in 2024, before generating positive profits of US$59m in 2025. The company is therefore projected to breakeven just over a year from now. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 61%, which is extremely buoyant. Should the business grow at a slower rate, it will become profitable at a later date than expected.
根據9位美國藥品分析師的說法,Avadel Pharmaceuticals即將盈虧平衡。他們預計該公司將在2024年遭受最終虧損,並在2025年創造5900萬美元的正利潤。因此該公司預計將在一年多的時間內實現盈虧平衡。該公司每年需要增長多少百分比才能達到這個目標?通過最佳擬合線,我們計算出平均年增長率爲61%,這是極其強勁的。如果該業務增長速度較慢,則將比預期晚獲得盈利。
![big](https://newsfile.futunn.com/public/NN-PersistNewsContentImage/7781/20240715/0-ff4419447038244b6de675db38426029-0-7b5d903be77954e5943ce0d072d367b3.png/big)
We're not going to go through company-specific developments for Avadel Pharmaceuticals given that this is a high-level summary, however, bear in mind that typically a pharma company has lumpy cash flows which are contingent on the drug and stage of product development the business is in. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.
我們不打算對Avadel Pharmaceuticals進行特定於公司的發展的詳細介紹,因爲這是一個高層次的概要,但請記住,通常藥品公司具有依賴於藥品和產品開發階段的波動現金流。因此,當公司處於投資期間時,高增長率並不罕見。
One thing we would like to bring into light with Avadel Pharmaceuticals is its relatively high level of debt. Generally, the rule of thumb is debt shouldn't exceed 40% of your equity, which in Avadel Pharmaceuticals' case is 44%. A higher level of debt requires more stringent capital management which increases the risk in investing in the loss-making company.
我們想要指出的一件事是Avadel Pharmaceuticals的相對高額債務水平。一般而言,規則是債務不應超過股本的40%,在Avadel Pharmaceuticals的情況下爲44%。更高的債務水平需要更嚴格的資本管理,從而增加了投資該虧損公司的風險。
Next Steps:
下一步:
This article is not intended to be a comprehensive analysis on Avadel Pharmaceuticals, so if you are interested in understanding the company at a deeper level, take a look at Avadel Pharmaceuticals' company page on Simply Wall St. We've also compiled a list of key aspects you should look at:
本文不旨在對Avadel Pharmaceuticals進行全面分析,因此如果您對深入了解該公司感興趣,請查看Simply Wall St上的Avadel Pharmaceuticals公司頁面。我們還編制了一份關鍵方面清單供您查看:
- Valuation: What is Avadel Pharmaceuticals worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Avadel Pharmaceuticals is currently mispriced by the market.
- Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Avadel Pharmaceuticals's board and the CEO's background.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
- 估值:Avadel Pharmaceuticals今天的市值是多少?未來的增長潛力已經反映在股價中嗎?我們免費的研究報告和圖表能夠幫助您了解股票的內在價值。
- 管理團隊:一支經驗豐富的管理團隊將增強我們對 avadel pharmaceuticals 業務的信懇智能 – 看看誰在公司董事會和CEO背景中擔任重要角色。
- 其他高表現的股票:是否有其他表現更好的股票並具有經過驗證的歷史記錄?查看這裏的免費列表。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
譯文內容由第三人軟體翻譯。